SickKids researchers identify three subtypes of high-grade gliomas with distinct treatment responses to provide precision care for patients.

In a major leap for cancer care at the University of Missouri, the School of Medicine and MU Health Care have launched their first clinical trial using a leading-edge therapy manufactured on campus at the university’s research reactor. The achievement also showcases the breadth of research capabilities across campus to bring a radiopharmaceutical from development, through testing, to human clinical trials.

Radiation therapy is highly effective at killing cancer cells, but it often harms healthy skin around the treatment area, a common side effect experienced by up to 95% of cancer patients undergoing treatment. In worst-case scenarios, it can result in delayed or halted treatment.  

Researchers at Houston Methodist Research Institute have now discovered a promising new approach that can protect patients from radiation-induced skin damage during cancer treatment.  

In a significant breakthrough for cancer immunotherapy, collaborative studies published simultaneously in Immunity & Inflammation and Nature have demonstrated a critical molecular mechanism that drives CD8⁺ T cells into a dysfunctional “exhausted” state within tumors. The studies reveal how chronic antigen exposure opens a molecular switch—the suppression of the FOXO1-KLHL6 axis—to promote T cells toward exhaustion, providing a promising new target for intervention.